Purchase this article with an account.
T. C. Kreutzer, A. H. Wolf, D. Kook, C. S. Alge-Priglinger, A. Hofer, R. Strauss, C. Haritoglou, A. Kampik, S. Priglinger; Intravitreal Bevacizumab for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion. Invest. Ophthalmol. Vis. Sci. 2007;48(13):301.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the effectiveness of intravitreal application of bevacizumab on retinal thickness and visual acuity in eyes with macular oedema following branch retinal vein occlusion (BRVO).
After signing the consent form thirtyfour patients with macular edema following BRVO were treated with at least two and up to six intravitreal injections of 1.25mg of bevacizumab in four weeks intervals and followed up for six month. At defined time points two and six weeks, as well at three month and the six month after study inclusion OCT scans and visual acuity scores (Snellen, ETDRS) were collected additionally to thorough clinical evaluation of the eyes.
Patients presented at a mean age of 69 years (range 44 - 86 years). Mean duration of symptoms from branch retinal vein occlusion was 40 weeks (range 1 - 300 weeks). Visual acuity at baseline showed mean results of 0.79 LogMAR (±0.39) and improved to a mean of 0.46 LogMAR (±0.38) at the six month control visit (P = 0.009). Cases achieved a mean of 45.3 (±19.0) letters on the ETDRS-chart at baseline and improved to a mean of 65.3 (±20.6) letters at the six month control visit (P = 0.003). Retinal thickness as measured by the OCT at baseline was 473µm (±120) and declined to a mean of 326µm (±90) at the six month control visit.
Intravitreal injections of 1.25mg bevacizumb seems to be an effective treatment for branch retinal vein occlusion and increases visual acuity even in cases with chronic macular oedema.
This PDF is available to Subscribers Only